Pharmacoeconomics

Papers
(The TQCC of Pharmacoeconomics is 9. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
Empirical Testing of Alternative Search Methods to Retrieve Utility Values for Health Economic Modelling189
Meeting the Challenges of Preference-Weighted Health-Related Quality-of-Life Measurement in Children160
Value of Innovative Multiple Myeloma Treatments from Patient and Healthcare Provider Perspectives: Evidence from a Discrete Choice Experiment104
The Impact of Tocilizumab Coverage on Health Equity for Inpatients with COVID-19 in the USA: A Distributional Cost-Effectiveness Analysis74
The Value of Flexible Vaccine Manufacturing Capacity: Value Drivers, Estimation Methods, and Approaches to Value Recognition in Health Technology Assessment66
Optimisation or Restriction? Unpacking the Logic Behind NICE Decisions63
Cost-Effectiveness Analysis of a New Second-Line Treatment Regimen for Advanced Intrahepatic Cholangiocarcinoma: Biomarker-Driven Targeted Therapy of Pemigatinib Versus 5-FU Chemotherapy53
Incorporating Dynamic Pricing in Cost-Effectiveness Analysis: Are Known Unknowns Valuable?53
The Egyptian EQ-5D-5L Extensive Pilot Study: Lessons Learned49
Bayesian Meta-Analysis: A Practical Introduction48
Advancing Methods to Measure and Reward Healthcare Innovation48
Cost Effectiveness of Strategies to Manage Atrial Fibrillation in Middle- and High-Income Countries: A Systematic Review48
Catalogues of EQ-5D-3L Health-Related Quality of Life Scores for 199 Chronic Conditions and Health Risks for Use in the UK and the USA47
Under-reporting of Validation Efforts for Health Economic Models Persists Despite the Availability of Validation Tools: A Systematic Review45
The Economic Burden of Inflammatory Arthritis: A Systematic Review43
Evaluating the Validation Process: Embracing Complexity and Transparency in Health Economic Modelling43
Cost-effectiveness Analysis of Tisagenlecleucel Versus Blinatumomab in Children and Young Adults with Acute Lymphoblastic Leukemia: Partitioned Survival Model to Assess the Impact of an Outcome-Based 42
Are We Capturing the Socioeconomic Burden of Rare Genetic Disease? A Scoping Review of Economic Evaluations and Cost-of-Illness Studies41
Caring for and Caring about in Economic Evaluation: Modelling the Family and Caregiving Effects38
Innovation Headroom for a Highly Accurate PD-L1 Companion Diagnostic in Non-small Cell Lung Cancer38
Comparative Analysis of Traditional and Pharmacometric-Based Pharmacoeconomic Modeling in the Cost-Utility Evaluation of Sunitinib Therapy34
Economic Burden Associated with Pulmonary Arterial Hypertension in the United States34
De Novo Cost-Effectiveness Model Framework for Nonalcoholic Steatohepatitis—Modeling Approach and Validation33
Impact of Influenza and Influenza-Like Illness on Work Productivity Outcomes: A Systematic Literature Review31
Market Transparency in Medicine Pricing: Pathways to Fair Pricing31
EQ-5D-Y-3L Value Sets, Valuation Methods and Conceptual Questions31
Modelling the Cost Effectiveness of Treatments for Parkinson’s Disease: An Updated Methodological Review31
A Framework for Reliable, Transparent, and Reproducible Population-Adjusted Indirect Comparisons31
Time to Close the Gap Between Guidelines and the Reimbursement Policy for Diabetes Treatment in Turkey29
Mixture and Non-mixture Cure Models for Health Technology Assessment: What You Need to Know29
Launch and Post-Launch Prices of Injectable Cancer Drugs in the US: Clinical Benefit, Innovation, Epidemiology, and Competition29
The Difference Method Approach for Sampling Order Constrained Parameters: An Improved Implementation and Important Limitations26
The Cost Effectiveness of Upgrading Cochlear Implant Sound Processors in Australia: A Novel Application of Individual-Level Microsimulation Models26
An Exploratory Analysis of the Cost-Effectiveness of a Multi-cancer Early Detection Blood Test Compared with Standard of Care Screening in Ontario, Canada26
Economic Evaluations of Treatments for Duchenne Muscular Dystrophy: The Caregiver QALY Trap26
Disease Severity Modifier in the NICE Single Technology Appraisal of Trastuzumab Deruxtecan: External Assessment Group Perspective26
Identifying and Comparing Intervention Cost Components in Remote Patient Monitoring: A Scoping Review25
The Value of Combination Vaccines in Children and Adults: More than the Sum of Their Parts25
Community Pharmacist Preferences for Providing a Dose Administration Aid Service in Australia: A Discrete Choice Experiment25
A Systematic Review of Methods for Estimating Productivity Losses due to Illness or Caregiving in Low- and Middle-Income Countries24
Caregiver Burden of Spinal Muscular Atrophy: A Systematic Review23
The Use of Real-World Data for Estimating Relative Treatment Effects in NICE Health Technology Assessment Submissions: A Review23
Measuring the Direct Medical Costs of Hospital-Onset Infections Using an Analogy Costing Framework22
A Machine Learning and Large Language Model Tool for Systematic Literature Reviews of Health Economic Evidence: A Validation Study22
Value-Based Indication-Specific Pricing and Weighted-Average Pricing: Estimated Price and Cost Savings for Cancer Drugs22
Prognostic Testing for Prostate Cancer—A Cost-Effectiveness Analysis Comparing a Prostatype P-Score Biomarker Approach to Standard Clinical Practice22
Value of Information for Clinical Trial Design: The Importance of Considering All Relevant Comparators22
Improving Transparency of Decision Models Through the Application of Decision Analytic Models with Omitted Objects Displayed (DAMWOOD)22
Drug Pricing Stewardship from Mark Cuban’s Cost Plus Generic Drug Program21
Cost-Effectiveness of SGLT2 Inhibitors in a Real-World Population: A MICADO Model-Based Analysis Using Routine Data from a GP Registry20
Quality Appraisal in Systematic Literature Reviews of Studies Eliciting Health State Utility Values: Conceptual Considerations20
Cost Effectiveness of Zanubrutinib Versus Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia20
A Systematic Review of the Cost-Effectiveness Analyses of Anaplastic Lymphoma Kinase (ALK) Inhibitors in Patients with Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)19
Acknowledgement to Referees19
Economic and Humanistic Burden of Osteoarthritis: An Updated Systematic Review of Large Sample Studies19
Comparing User-Written Codes for Performing Economic Evaluations in Stata19
Psychometric Performance Comparison of the Adapted versus Original Versions of the EQ-5D-Y-3L and -Y-5L in Proxy Respondents for 2- to 4-Year-Olds19
Comparison of EQ-5D-Y-3L Utility Scores Using Nine Country-Specific Value Sets in Chinese Adolescents19
Cost-Effectiveness Analysis of Nirsevimab for Preventing Respiratory Syncytial Virus-Related Lower Respiratory Tract Disease in Dutch Infants: An Analysis Including All-Infant Protection18
Application of Multi-level Network Meta-Regression in the NICE Technology Appraisal of Quizartinib for Induction, Consolidation and Maintenance Treatment of Newly Diagnosed FLT3-ITD-Positive Acute Mye18
Re-anchoring the Value of Innovative Therapies in NICE Decision Making When Comparators are Cost Ineffective: A Case Study of Late-Onset Pompe Disease18
Cost Effectiveness of Difelikefalin Compared to Standard Care for Treating Chronic Kidney Disease Associated Pruritus (CKD-aP) in People with Kidney Failure Receiving Haemodialysis18
Modelling Health State Utilities as a Transformation of Time to Death in Patients with Non-Small Cell Lung Cancer17
A Systematic Review of Modeling Approaches to Evaluate Treatments for Relapsed Refractory Multiple Myeloma: Critical Review and Considerations for Future Health Economic Models17
Examining Consistency Across NICE Single Technology Appraisals: A Review of Appraisals for Paroxysmal Nocturnal Haemoglobinuria17
A Proposal of a Cost-Effectiveness Modeling Approach for Heart Failure Treatment Assessment: Considering the Short- and Long-Term Impact of Hospitalization on Event Rates17
Balancing Innovation and Access: Insights from AIM’s Fair Pricing Model and Its Current and Future Applications16
Systematic Literature Review to Identify Cost and Resource Use Data in Patients with Early-Stage Non-small Cell Lung Cancer (NSCLC)16
Accounting for Genomic Testing Costs in Cost-Effectiveness Evaluations: Challenges and Lessons Learned from the NICE Single Technology Appraisal of Erdafitinib for Treating Unresectable or Metastatic 16
Comparing Generic Paediatric Health-Related Quality-of-Life Instruments: A Dimensionality Assessment Using Factor Analysis16
Modelling the Cost-Effectiveness of Diagnostic Tests15
Capturing Value Attributes in the Economic Evaluation of Ceftazidime with Avibactam for Treating Severe Aerobic Gram-Negative Bacterial Infections in the United Kingdom15
Measuring the Indirect Cost of Illness Using EQ-5D-5L While Accounting for Job Characteristics15
Cost-Effectiveness of Thrombopoietin Mimetics in Patients with Thrombocytopenia: A Systematic Review15
Development and Validation of txSim: A Model of Advanced Lung Cancer Treatment in Australia15
Comment on “The Importance of Structured Expert Elicitation to Inform Outcomes Following Treatment Discontinuation: Evidence Assessment Group Perspective”15
Comment on “An Integrated Pharmacokinetic–Pharmacodynamic–Pharmacoeconomic Modeling Method to Evaluate Treatments for Adults with Schizophrenia”15
Uncertainty in Matching-Adjusted Indirect Comparisons Using Real-World Evidence: Evidence Assessment Group Perspective15
Childhood Transitions Between Weight Status Categories: Evidence from the UK Millennium Cohort Study14
Health Care Resource Utilization and Costs Associated with US Medicaid Sobriety Restrictions on Direct-Acting Antivirals for Hepatitis C Virus: A Retrospective Claims Database Analysis14
The Cost-Effective Price of Lecanemab for Patients with Early Alzheimer’s Disease in Sweden14
Budget Impact of Introducing Fixed-Duration Mosunetuzumab for the Treatment of Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic Therapy in the USA14
How do Health State Values Differ When Respondents Consider Adults Versus Children Living in Those States? A Systematic Review13
Transporting Comparative Effectiveness Evidence Between Countries: Considerations for Health Technology Assessments13
Cost-Utility Analysis of Calcitonin Gene-Related Peptide Monoclonal Antibodies for Patients with Episodic Migraine Headache in the USA13
Systematic Review of the Relative Social Value of Child and Adult Health13
A Guide to an Iterative Approach to Model-Based Decision Making in Health and Medicine: An Iterative Decision-Making Framework13
The Costs of Dementia in Europe: An Updated Review and Meta-analysis13
Economic Implications of Endometriosis: A Review13
Content Comparison of Quality-of-Life Instruments Used in Economic Evaluations of Sleep Disorder Interventions: A Systematic Review12
Is Risk-Stratifying Patients with Colorectal Cancer Using a Deep Learning-Based Prognostic Biomarker Cost-Effective?12
Economic Evaluation of Interventions to Reduce Antimicrobial Resistance: A Systematic Literature Review of Methods12
Informal Caregiving Provision for Disabled or Elderly in the Families and Work Productivity: Evidence from 11 Waves of an Australian Population-Based Cohort12
Examining the Effect of Depicting a Patient Affected by a Negative Reimbursement Decision in Healthcare on Public Disagreement with the Decision12
Challenges and Opportunities in Interdisciplinary Research and Real-World Data for Treatment Sequences in Health Technology Assessments12
Current Practices for Accounting for Preference Heterogeneity in Health-Related Discrete Choice Experiments: A Systematic Review12
Considerations Around the Inclusion of Children and Young People’s Time in Economic Evaluation: Findings from an International Delphi Study12
Societal Versus Healthcare Perspectives on the Cost Effectiveness of Ocrelizumab for Treatment of Primary Progressive Multiple Sclerosis in Aotearoa New Zealand12
Cost-Effectiveness Analysis of MammaPrint® to Guide the Use of Endocrine Therapy in Patients with Early-Stage Breast Cancer11
Cost-Effectiveness Analysis of Tofacitinib Compared with Biologics in Biologic-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan11
Evidence Following Conditional NICE Technology Appraisal Recommendations: A Critical Analysis of Methods, Quality and Risk of Bias11
A Value Set for the EQ-5D-Y-3L in the Netherlands11
A Systematic Review of the Economic Burden of Prostate Cancer: Direct and Indirect Cost Perspectives11
Measuring Effectiveness Based on Patient Experience (Instead of QALYs) in US Value Assessments10
MPES-R: Multi-Parameter Evidence Synthesis in R for Survival Extrapolation—A Tutorial10
Correction: Health-Related Quality-of-Life Outcomes of Very Preterm or Very Low Birth Weight Adults: Evidence From an Individual Participant Data Meta-Analysis10
Universal Health Coverage of Opioid Agonist Treatment in Norway: An Equity-Adjusted Economic Evaluation10
HTA Barriers for Conditional Approval Drugs10
Incorporating Complexity and System Dynamics into Economic Modelling for Mental Health Policy and Planning10
Correction: How do Health State Values Differ When Respondents Consider Adults Versus Children Living in Those States? A Systematic Review10
A Promising Approach to Optimizing Sequential Treatment Decisions for Depression: Markov Decision Process10
Effects and Costs of Hepatitis C Virus Elimination for the Whole Population in China: A Modelling Study9
Endovascular Treatment for Acute Ischemic Stroke: A Methodological Systematic Review of Health Economic Decision Modeling Studies9
Cost-Utility Analyses of Systemic Treatments for Psoriasis and Psoriatic Arthritis in the UK: A Systematic Review of Modelling Methods9
Analytical Considerations When Anchoring Discrete Choice Experiment Values Using Composite Time Trade-Off Data: The Case of EQ-5D-Y-3L9
Accounting for Adverse Events Following Immunization in Economic Evaluation: Systematic Review of Economic Evaluations of Pediatric Vaccines Against Pneumococcus, Rotavirus, Human Papillomavirus, Meni9
Economic Evaluation of Pre-emptive Pharmacogenetic Panel Testing versus No Genetic Testing in a Multi-ethnic Asian Population9
Beyond the States: Developing a Discrete Event Simulation Model Using R9
Prediction Models for Individual-Level Healthcare Costs Associated with Cardiovascular Events in the UK9
Informal Care Costs According to Age and Proximity to Death to Support Cost-Effectiveness Analyses9
Economic Evaluation of Interventions for Children with Neurodevelopmental Disorders: Practical Guidance9
0.22929310798645